Cart
sales@molnova.com
Alisol G
CAS No. 155521-46-3
Alisol G( Alisol-G | 25-Anhydroalisol A )
Catalog No. M29616 CAS No. 155521-46-3
Alisol G is isolated from Rhizoma Alismatis and exhibits hCE2 inhibitory effects.
Purity : >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| Size | Price / USD | Stock | Quantity |
| 1 mL x 10 mM in DMSO | 188 | In Stock |
|
| 2MG | 112 | In Stock |
|
| 5MG | 187 | In Stock |
|
| 10MG | 275 | In Stock |
|
| 25MG | 465 | In Stock |
|
| 50MG | 649 | In Stock |
|
| 100MG | Get Quote | In Stock |
|
| 200MG | Get Quote | In Stock |
|
| 500MG | Get Quote | In Stock |
|
| 1G | Get Quote | In Stock |
|
Biological Information
-
Product NameAlisol G
-
NoteResearch use only, not for human use.
-
Brief DescriptionAlisol G is isolated from Rhizoma Alismatis and exhibits hCE2 inhibitory effects.
-
DescriptionAlisol G is isolated from Rhizoma Alismatis and exhibits hCE2 inhibitory effects.
-
In Vitro——
-
In Vivo——
-
SynonymsAlisol-G | 25-Anhydroalisol A
-
PathwayOthers
-
TargetOther Targets
-
Recptor——
-
Research Area——
-
Indication——
Chemical Information
-
CAS Number155521-46-3
-
Formula Weight472.71
-
Molecular FormulaC30H48O4
-
Purity>98% (HPLC)
-
Solubility——
-
SMILES[H][C@@]12CCC3(C)C(C(O)CC4=C(CC[C@]34C)C(C)C[C@H](O)[C@@H](O)C(C)=C)[C@@]1(C)CCC(=O)C2(C)C
-
Chemical Name——
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
molnova catalog
related products
-
Pomalidomide-PEG2-OH
Pomalidomide-PEG2-OH enables the synthesis of molecules for targeted protein degradation and PROTAC (proteolysis-targeting chimeras) technology.
-
Blebbistatin (b)
(+)-Blebbistatin is the inactive enantiomer of (–)-Blebbistatin. (–)-Blebbistatin is a selective myosin II ATPase inhibitor.
-
demethyldaphnoretin-...
Demethyldaphnoretin-7-O-glucoside is a natural product that is isolated from Daphne oleoides Schreber subsp. kurdica (DOK). In Turkish traditional medicine, the aerial parts of DOK have been used to treat malaria, rheumatism and for wound healing.
